Kymriah® (tisagenlecleucel), a Chimeric antigen receptor T cell (CAR-T) one-time treatment, will be the first commercially approved CAR-T therapy to be manufactured in Australia
Providing manufacturing capabilities in Australia will help reduce transportation time previously from overseas sites, facilitating faster access to Kymriah for patient
Cell Therapies located within the Peter MacCallum Cancer Centre, Melbourne, has become the first approved local CAR-T commercial manufacturing site for Kymriah
Australia is one of seven manufacturing sites worldwide as part of the extensive Novartis CAR-T manufacturing network
With COVID-19 restrictions significantly impacting on traditional ways of working, Novartis Australia is offering associates the choice to decide how, where and when they work.
Novartis’ new flexible working model forms the basis of the organisation’s long-term vision for redefining how associates create the greatest impact in their role.
The “unbossed” future working model empowers associates to take personal responsibility to inform managers about their working schedule and align with teammates for effective collaboration.
COVID-19 is significantly impacting patient organisations’ ability to undertake their critical work as funds and resources are diverted to COVID-19 initiatives
As these patient organisations are altering their essential services to provide greater proactive outreach to patients, revenues from donations and community initiatives have slowed, or even stopped
Novartis Australia has rolled out funding for COVID-19 related programs, support for mental health and stepped up its promotion of partner patient organisation campaigns
Novartis Australia, and its generics and biosimilars division Sandoz, has confirmed that it will be working with the Australian government to provide an initial supply of generic hydroxychloroquine to support the COVID-19 pandemic response.
Novartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and healthcare professionals.
Novartis in Australia and New Zealand continues to closely monitor and respond to the coronavirus (COVID-19) situation. Our priority is to ensure the health and safety of our people, patients, and healthcare professionals.
Up to 8,800 hospital admissions and hundreds of deaths could be prevented, according to first Seasonal Vulnerability Report1
Thousands of older Australians are being hospitalised as temperatures plummet across Australia, with a new report revealing a 32 per cent spike in admissions during winter compared to summer for deadly and common heart conditions.1
Novartis today announced that the Therapeutic Goods Administration (TGA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis. The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.
